Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Alterity Therapeutics (ATHE) EPS (Weighted Average and Diluted) (2016 - 2019)

Alterity Therapeutics has reported EPS (Weighted Average and Diluted) over the past 3 years, most recently at -$3.45 for Q4 2018.

  • For Q4 2018, EPS (Weighted Average and Diluted) fell 34.29% year-over-year to -$3.45; the TTM value through Dec 2018 reached -$3.45, down 34.29%, while the annual FY2025 figure was -$0.12, 63.89% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2018 was -$3.45 at Alterity Therapeutics, down from -$2.57 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$2.52 in Q4 2016 and troughed at -$3.45 in Q4 2018.
  • A 3-year average of -$2.84 and a median of -$2.57 in 2017 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): fell 1.87% in 2017 and later plummeted 34.29% in 2018.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$2.52 in 2016, then dropped by 1.87% to -$2.57 in 2017, then tumbled by 34.29% to -$3.45 in 2018.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ATHE at -$3.45 in Q4 2018, -$2.57 in Q4 2017, and -$2.52 in Q4 2016.